Sionna Therapeutics (NASDAQ:SION) Director Sells $1,295,628.54 in Stock

Sionna Therapeutics, Inc. (NASDAQ:SION) Director Peter Thompson sold 29,063 shares of the firm’s stock in a transaction that occurred on Tuesday, February 3rd. The shares were sold at an average price of $44.58, for a total transaction of $1,295,628.54. Following the transaction, the director directly owned 3,530,702 shares in the company, valued at approximately $157,398,695.16. The trade was a 0.82% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

Sionna Therapeutics Stock Up 2.4%

Shares of SION opened at $36.11 on Friday. The company’s fifty day moving average is $41.08 and its 200-day moving average is $32.95. Sionna Therapeutics, Inc. has a 12 month low of $7.26 and a 12 month high of $45.00. The firm has a market cap of $1.61 billion and a price-to-earnings ratio of -7.41.

Sionna Therapeutics (NASDAQ:SION) last issued its quarterly earnings data on Wednesday, November 5th. The company reported ($0.46) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.52) by $0.06.

Analysts Set New Price Targets

A number of research analysts have commented on the stock. Weiss Ratings restated a “sell (e+)” rating on shares of Sionna Therapeutics in a research note on Monday, December 29th. BTIG Research restated a “buy” rating and set a $58.00 target price on shares of Sionna Therapeutics in a research report on Wednesday, January 14th. Wall Street Zen upgraded Sionna Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, December 13th. Raymond James Financial reissued a “strong-buy” rating and set a $53.00 price objective on shares of Sionna Therapeutics in a report on Monday, January 5th. Finally, Lifesci Capital started coverage on shares of Sionna Therapeutics in a research note on Tuesday, December 23rd. They issued an “outperform” rating and a $60.00 target price on the stock. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and two have given a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $45.43.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Goldman Sachs Group Inc. bought a new stake in Sionna Therapeutics during the 1st quarter worth about $667,000. Woodline Partners LP acquired a new stake in shares of Sionna Therapeutics in the first quarter valued at approximately $837,000. Aberdeen Group plc raised its position in Sionna Therapeutics by 27.4% in the 2nd quarter. Aberdeen Group plc now owns 950,547 shares of the company’s stock worth $16,492,000 after purchasing an additional 204,583 shares during the last quarter. Geode Capital Management LLC raised its position in Sionna Therapeutics by 113.4% in the 2nd quarter. Geode Capital Management LLC now owns 289,275 shares of the company’s stock worth $5,020,000 after purchasing an additional 153,712 shares during the last quarter. Finally, Police & Firemen s Retirement System of New Jersey acquired a new position in Sionna Therapeutics during the 2nd quarter worth $45,000.

Sionna Therapeutics Company Profile

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.